title: Analyses of the combination of 6-MP and dasatinib in cell culture.
abstract: A major tenet of cancer therapeutics is that combinations of anticancer agents with different mechanisms of action and different toxicities may be effective treatment regimens. Evaluation of additivity/synergy in cell culture may be used to identify drug combination opportunities and to assess risk of additive/synergistic toxicity. The combination of 6-mercaptopurine and dasatinib was assessed for additivity/synergy using the combination index (CI) method and a response surface method in six human tumor cell lines including MCF-7 and MDA-MB‑468 breast cancer, NCI-H23 and NCI-H460 non‑small cell lung cancer, and A498 and 786-O renal cell cancer, based on two experimental end‑points: ATP content and colony formation. Clonal colony formation by human bone marrow CFU-GM was used to assess risk of enhanced toxicity. The concentration ranges tested for each drug were selected to encompass the clinical Cmax concentrations. The combination regimens were found to be additive to sub‑additive by both methods of data analysis, but synergy was not detected. The non-small cell lung cancer cell lines were the most responsive among the tumor lines tested and the renal cell carcinoma lines were the least responsive. The bone marrows CFU-GM were more sensitive to the combination regimens than were the tumor cell lines. Based upon these data, it appears that the possibility of enhanced efficacy from combining 6-mercaptopurine (6-MP) and dasatinib would be associated with increased risk of severe bone marrow toxicity, so the combination is unlikely to provide a therapeutic advantage for treating solid tumor patients where adequate bone marrow function must be preserved.
authors: Molecular Pharmacology Branch, Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, Frederick National Laboratory for Cancer Research, Frederick, MD 21702, USA. kaurgu@mail.nih.gov
authors: Gurmeet
authors: G
authors: Kaur
authors: Holger
authors: H
authors: Behrsing
authors: Ralph E
authors: RE
authors: Parchment
authors: Myrtle Davis
authors: MD
authors: Millin
authors: Beverly A
authors: BA
authors: Teicher
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage; D000069439:Dasatinib; D004357:Drug Synergism; D006801:Humans; D066298:In Vitro Techniques; D061986:MCF-7 Cells / Q000187:drug effects; D015122:Mercaptopurine / Q000008:administration & dosage* / Q000633:toxicity; D009369:Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D011743:Pyrimidines / Q000008:administration & dosage* / Q000633:toxicity; D013844:Thiazoles / Q000008:administration & dosage* / Q000633:toxicity; D014410:Tumor Stem Cell Assay
chemical_list: D011743:Pyrimidines; D013844:Thiazoles; D015122:Mercaptopurine; D000069439:Dasatinib
references: Nat Cell Biol. 2010 Dec;12(12):1166-76
references: 21076410
references: Cancer Res. 1976 Oct;36(10):3779-83
references: 821607
references: Cancer Res. 1969 Dec;29(12):2292-9
references: 4905235
references: Cancer Res. 1985 Mar;45(3):1187-97
references: 2578876
references: Cancer Res. 1965 May;25:539-43
references: 14297492
references: Clin Cancer Res. 2004 Oct 1;10(19):6722-31
references: 15475463
references: Biochem J. 1981 Mar 1;193(3):799-803
references: 6895465
references: Ann N Y Acad Sci. 1954 Dec 6;60(2):195-9
references: 14350523
references: Mol Cancer Ther. 2003 Sep;2(9):929-32
references: 14555712
references: Science. 1989 Apr 7;244(4900):41-7
references: 2649979
references: In Vitro. 1976 Sep;12(9):623-7
references: 1010528
references: Bioorg Med Chem Lett. 2011 May 15;21(10):3152-8
references: 21450467
references: Pharm Res. 1998 Jul;15(7):1069-76
references: 9688062
references: J Pharmacol Exp Ther. 2004 Sep;310(3):981-6
references: 15175417
references: Int J Radiat Oncol Biol Phys. 1979 Jan;5(1):85-91
references: 422420
references: Clin Cancer Res. 2007 Jan 15;13(2 Pt 2):764s-769s
references: 17255307
references: J Clin Oncol. 2011 Mar 1;29(7):839-44
references: 21263099
references: J Natl Cancer Inst. 1996 Jun 5;88(11):699-700
references: 8637018
references: Toxicol Sci. 2003 Oct;75(2):355-67
references: 12883091
references: In Vitro. 1978 Sep;14(9):779-86
references: 721102
references: Proc Natl Acad Sci U S A. 2003 Jun 24;100(13):7977-82
references: 12799470
references: Annu Rev Pharmacol Toxicol. 2003;43:199-231
references: 12195027
references: Cancer Res. 1997 Dec 1;57(23):5217-20
references: 9393737
references: Cancer Chemother Pharmacol. 1997;39(5):467-72
references: 9054963
references: Ther Clin Risk Manag. 2009 Apr;5(2):281-9
references: 19536317
references: Expert Opin Drug Discov. 2009 Dec;4(12):1295-305
references: 23480467
references: Clin Cancer Res. 2012 Oct 1;18(19):5489-98
references: 22837181
references: Oncogene. 2008 Jul 17;27(31):4380-4
references: 18362889
references: Nature. 1989 Dec 7;342(6250):705-8
references: 2531845
references: Br J Clin Pharmacol. 2006 Jul;62(1):15-26
references: 16842375
references: Cancer Res. 1980 Oct;40(10):3502-7
references: 6108156
references: Mol Cell Proteomics. 2009 Dec;8(12):2796-808
references: 19651622
references: Science. 1989 Oct 27;246(4929):491-4
references: 2554494
references: J Natl Cancer Inst. 1973 Nov;51(5):1409-16
references: 4357757
references: J Natl Cancer Inst. 1973 Nov;51(5):1417-23
references: 4357758
references: Oncogene. 1992 Jan;7(1):171-80
references: 1311061
references: Blood. 1998 Nov 15;92(10):3569-77
references: 9808549
references: Front Biosci (Elite Ed). 2010 Jan 01;2(1):241-9
references: 20036874
references: Antiviral Res. 1990 Oct-Nov;14(4-5):181-205
references: 2088205
references: Cancer Res. 2010 Jan 15;70(2):440-6
references: 20068163
references: Nat Biotechnol. 2007 Sep;25(9):1035-44
references: 17721511
references: J Biol Chem. 1960 Feb;235:429-32
references: 14441085
references: Stat Med. 2003 Jul 15;22(13):2091-100
references: 12820275
references: Mol Cancer Ther. 2008 Oct;7(10):3212-22
references: 18852125
references: Clin Cancer Res. 2004 Dec 1;10(23):7994-8004
references: 15585635
references: Pharmacol Rev. 2006 Sep;58(3):621-81
references: 16968952
references: Cancer Res. 1990 Sep 1;50(17):5318-27
references: 2386940
references: Nat Rev Cancer. 2008 Jan;8(1):24-36
references: 18097462
references: In Vitro. 1978 Nov;14(11):911-5
references: 730202
references: Cancer Res. 1983 Jun;43(6):2831-5
references: 6850594
references: Biochem J. 1997 Jun 15;324 ( Pt 3):761-75
references: 9210399
references: Cancer Res. 2006 Apr 1;66(7):3351-4, discussion 3354
references: 16585151
references: J Natl Cancer Inst. 1977 Feb;58(2):209-14
references: 833871